Teal Health raised $22 million to advance an at-home HPV cervical cancer screening device in the clinic. The Series A round was led by .406 Ventures, with additional backing from Emerson Collective (managed by Yosemite), Forerunner, Serena Ventures, and Japan-based MPower Partners. The financing highlights continued momentum in decentralized diagnostics aimed at improving screening uptake and earlier detection. With cervical cancer prevention increasingly tied to test access and patient compliance, an at-home HPV pathway is positioned as a direct lever for earlier intervention. The company’s push into clinical development underscores how diagnostics funding is aligning with healthcare access goals rather than only clinical performance metrics.